FIELD: medicine.
SUBSTANCE: there are offered versions of human IL22 specific antibodies. The antibodies are differed by the fact that they are produced of different hybridomas PTA-7312, PTA-7315, and PTA-7319. The PTA-7312 antibody is characterised by the fact that it inhibits STAT3 activation by reaching IC50 in the concentration 0.14 mcg/ml whereas the PTA-7315, PTA-7319 antibodies are characterised by Kd less than 1 nM.
EFFECT: use of the invention can find further application in therapy of the IL22 mediated immune disorders.
24 cl, 41 dwg, 1 tbl, 26 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-IL-22R-ANTIBODIES | 2017 |
|
RU2758721C2 |
| METHODS OF TREATING CANCER USING ANTAGONISTS BINDING TO PD-1 AXIS AND TIGIT INHIBITORS | 2014 |
|
RU2702108C2 |
| METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND TIGIT INHIBITORS | 2014 |
|
RU2825390C2 |
| ANGIOPOIETIC ANGIOPOIETIN-LIKE PROTEIN 4 INHIBITORS, IN COMBINATIONS AND APPLICATION | 2005 |
|
RU2392966C2 |
| NEW COMPOSITION AND METHODS FOR THERAPY OF IMMNUNE-ASSOCIATED DISEASES WITH IMMUNITY | 2004 |
|
RU2375078C2 |
| LIGAND GITR AND MOLECULES AND ANTIBODIES BOUND WITH LIGAND GITR, AND VERSIONS OF THEIR APPLICATION | 2004 |
|
RU2369636C2 |
| INHIBITION OF DISSEMINATION OF TUMOUR USING Bv8 OR G-CSF ANTAGONISTS | 2010 |
|
RU2567803C2 |
| HETERODIMERIC POLIPEPTIDES IL-17 A/F AND POSSIBILITIES OF THEIR THERAPEUTIC APPLICATION | 2007 |
|
RU2440134C2 |
| MONOCLONAL ANTIBODIES AGAINST IL-21 OF HUMAN BEING | 2008 |
|
RU2504552C2 |
| TRISPECIFIC IL-17A, IL-17F AND OTHER PROINFLAMMATORY MOLECULES ANTIBODIES | 2016 |
|
RU2680011C2 |
